Number of Shares and Voting Rights of ADOCIA as of May 31st, 2021
10 Giugno 2021 - 6:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA (Paris:ADOC), a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical stage biopharmaceutical company focused on
treatment of diabetes, obesity and metabolic diseases with
innovative formulations of approved proteins, releases its total
number of outstanding shares as well as its voting rights as of May
31st, 2021.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting rights (2)
May
05/31/2021
7 021 754
9 793 487
9 760 135
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
ADOCIA is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes,
obesity and metabolic diseases. In the diabetes field, Adocia’s
portfolio of injectable treatments is among the largest and most
differentiated of the industry, featuring five clinical-stage
products and several pre-clinical products. The proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and/or safety of therapeutic proteins while making
them easier for patients to use. Adocia customizes BioChaperone to
each protein for a given application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: two combinations of rapid acting insulin
analogs and Pramlintide (BioChaperone® Lispro Pram and
BioChaperone® Aspart Pram), a combination of insulin glargine with
GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In
addition, there are two bi-hormonal products for the treatment of
obesity: a combination of glucagon and exenatide (BioChaperone®
Glucagon Exenatide) and a combination of pramlintide and exenatide
(PramExe).
Adocia recently added a preclinical program to its pipeline with
a cell therapy initiative focused on development of a hydrogel
scaffold for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 20, 2021
(a copy of which is available at www.adocia.com) and to the
development of economic conditions financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Adocia to be
materially different from such forward-looking statements. This
press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210610005723/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu Ph: +49 89 210
228 0
The Ruth Group Adocia Investor Relations USA James
Salierno Vice-President jsalierno@theruthgroup.com Ph.: +1 646
536 7035
Grafico Azioni Adocia (EU:ADOC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Adocia (EU:ADOC)
Storico
Da Apr 2023 a Apr 2024
